Samsung Bioepis Australia has sued fellow biotechnology company Fresenius Kabi over a biosimilar of top selling immunosuppressant drug Humira, saying the invention ‘does not achieve the promise’ of a better formulation using fewer ingredients.
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.
Publisher HarperCollins has filed a special leave application with the High Court seeking to challenge a decision that revived a defamation case by a psychiatrist over a book covering the controversial deep sleep therapy at the Chelmsford Private Hospital in the 1970s.
German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.
A judge has dismissed a proceeding against the New South Wales government over a mandate requiring healthcare workers to be vaccinated against COVID-19, saying the applicant’s constitutional case was “legally misconceived and must be rejected.”
US medical device maker Boston Scientific has agreed to pay $105 million to settle a class action on behalf of Australian women implanted with one or more of the company’s pelvic mesh or sling products.
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.
A former Sigma Healthcare executive has been sentenced to a suspended term of 14 months’ in prison after pleading guilty to trading on insider information.
A class action investigation is underway against Cosmos Clinics Australia after an investigative report by Fairfax uncovered what it said was a “litany of troubling practices” at its clinics around Australia.
A judge has dismissed a case seeking to force Nine to hand over draft versions of a 60 Minutes episode and related stories, after an appeals court threw out orders that would have forced production of the material.